Difference between revisions of "List of AM cannabinoids"
From Wiki Weed
(Created page with "Alexandros Makriyannis is a professor in the Department of Medicinal Chemistry at Northeastern University, where his research group has synthesized many new compounds with can...") |
|||
| (7 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
Alexandros Makriyannis is a professor in the Department of Medicinal Chemistry at Northeastern University, where his research group has synthesized many new compounds with cannabinoid activity. Some of those are: | Alexandros Makriyannis is a professor in the Department of Medicinal Chemistry at Northeastern University, where his research group has synthesized many new compounds with cannabinoid activity. Some of those are: | ||
| − | AM-087 — an analgesic CB1 agonist derived from Δ8THC substituted with a side chain on the 3-position, it has a Ki of 0.43nM making it roughly 100x as potent as THC. | + | |
| − | AM-251 — an inverse agonist at the CB1 cannabinoid receptor that is structurally related to SR141716A (rimonabant), but has a higher binding affinity with a Ki value of 7.5nM. | + | *[[AM-087]] — an analgesic CB1 agonist derived from Δ8THC substituted with a side chain on the 3-position, it has a Ki of 0.43nM making it roughly 100x as potent as THC. |
| − | AM-281 — N-(morpholin-4-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide | + | |
| − | AM-356 — a synthetically created stable chiral analog of anandamide, it acts on the cannabinoid receptors with a Ki of 17.9nM at CB1 and 868nM at CB2. | + | *[[AM-251]] — an inverse agonist at the CB1 cannabinoid receptor that is structurally related to SR141716A ([[rimonabant]]), but has a higher binding affinity with a Ki value of 7.5nM. |
| − | AM-374 — palmitylsulfonyl fluoride | + | |
| − | AM-381 — stearylsulfonyl fluoride | + | *AM-281 — N-(morpholin-4-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide |
| − | AM-404 — an active metabolite of paracetamol (acetaminophen) and a likely inhibitor of fatty acid amide hydrolase (FAAH) | + | |
| − | AM-411 — an adamantyl-substituted derivative of Δ8THC, it is a potent and fairly selective CB1 full agonist with a Ki of 6.80nM. It is also a moderately potent CB2 agonist with a Ki of 52.0nM. | + | *AM-356 — a synthetically created stable chiral analog of anandamide, it acts on the cannabinoid receptors with a Ki of 17.9nM at CB1 and 868nM at CB2. |
| − | AM-630 — a potent and selective inverse agonist for the cannabinoid receptor CB2, with a Ki of 32.1nM at CB2 and 165x selectivity over CB1, at which it acts as a weak partial agonist. | + | |
| − | AM-661 — 1-(N-methyl-2-piperidine)methyl-2-methyl-3-(2-iodo)benzoylindole | + | *AM-374 — palmitylsulfonyl fluoride |
| − | AM-678 — another name for JWH-018, it is a full agonist at both cannabinoid receptors with some selectivity for CB2. | + | |
| − | AM-679 — an iodobenzoylindole which acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5nM at CB1 and 49.5nM at CB2. | + | *AM-381 — stearylsulfonyl fluoride |
| − | AM-694 — an iodobenzoylindole which acts as a potent and selective agonist for the CB1 cannabinoid receptor, with a Ki of 0.08nM at CB1 and 18x selectivity over the related CB2 receptor (1.44nM). | + | |
| − | AM-735 — 3-bornyl-Δ8-THC, a mixed CB1 / CB2 agonist with Ki of 8.9nM at CB1 and 7.4nM at CB2. | + | *[[AM-404 ]]— an active metabolite of paracetamol (acetaminophen) and a likely inhibitor of fatty acid amide hydrolase (FAAH) |
| − | AM-855 — an analgesic derivative of Δ8tetrahydrocannabinol, it is an agonist at both CB1 and CB2 with moderate selectivity for CB1, with a Ki of 22.3nM at CB1 and 58.6nM at CB2. | + | |
| − | AM-881 — a chlorine-substituted stereoisomer of anandamide whose Ki = 5.3nM at CB1 and 95nM at CB2. | + | *[[AM-411 ]]— an adamantyl-substituted derivative of Δ8THC, it is a potent and fairly selective CB1 full agonist with a Ki of 6.80nM. It is also a moderately potent CB2 agonist with a Ki of 52.0nM. |
| − | AM-883 — an allyl-substituted stereoisomer of anandamide whose Ki = 9.9nM at CB1 and 226nM at CB2. | + | |
| − | AM-905 — a potent and reasonably selective agonist for the CB1 cannabinoid receptor, with a Ki of 1.2nM at CB1 and 5.3nM at CB2. | + | *[[AM-630 ]]— a potent and selective inverse agonist for the cannabinoid receptor CB2, with a Ki of 32.1nM at CB2 and 165x selectivity over CB1, at which it acts as a weak partial agonist. |
| − | AM-906 — a potent and dodecally selective agonist for the CB1 cannabinoid receptor, with a Ki of 0.8nM at CB1 and 9.5nM at CB2. | + | |
| − | AM-919 — a potent agonist at both CB1 and CB2 with moderate selectivity for CB1, with a Ki of 2.2nM at CB1 and 3.4nM at CB2. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families. | + | *AM-661 — 1-(N-methyl-2-piperidine)methyl-2-methyl-3-(2-iodo)benzoylindole |
| − | AM-926 — a potent agonist at both CB1 and CB2 with moderate selectivity for CB1, with a Ki of 2.2nM at CB1 and 4.3nM at CB2. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families. | + | |
| − | AM-938 — a potent agonist at both CB1 and CB2 with quadruple selectivity for CB2, with a Ki of 1.2nM at CB1 and 0.3nM at CB2. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families. | + | *[[AM-678 ]]— another name for [[JWH-018]], it is a full agonist at both cannabinoid receptors with some selectivity for CB2. |
| − | AM-1116 — a dimethylated stereoisomer of anandamide whose Ki = 7.4nM at CB1. | + | |
| − | AM-1172 — an endocannabinoid analog specifically designed to be a potent and selective inhibitor of AEA uptake that is resistant to FAAH hydrolysis. | + | *[[AM-679 (cannabinoid) ]]— an iodobenzoylindole which acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5nM at CB1 and 49.5nM at CB2. |
| − | AM-1220 — a potent and selective analgesic CB1 agonist (as racemate) with a Ki of 3.88nM at CB1 and 73.4nM at CB2, giving it 19x selectivity for CB1. (R) enantiomer has around 1000x higher affinity for CB1 than (S) enantiomer. | + | |
| − | AM-1221 — a potent and selective CB2 agonist with a Ki of 0.28nM at CB2 and 52.3nM at CB1, giving it a selectivity of almost 187x. | + | *[[AM-694]] — an iodobenzoylindole which acts as a potent and selective agonist for the CB1 cannabinoid receptor, with a Ki of 0.08nM at CB1 and 18x selectivity over the related CB2 receptor (1.44nM). |
| − | AM-1235 — a moderately CB1 selective agonist, with a Ki of 1.5nM at CB1 and 20.4nM at CB2, giving it a selectivity of around 13x. | + | |
| − | AM-1241 — a potent and selective analgesic CB2 agonist with a Ki of 3.4nM at CB2 and 80x selectivity over CB1. | + | *AM-735 — 3-bornyl-Δ8-[[THC]], a mixed CB1 / CB2 agonist with Ki of 8.9nM at CB1 and 7.4nM at CB2. |
| − | AM-1248 — a moderately potent agonist with some selectivity for CB1, containing an unusual 3-(adamant-1-oyl) substitution on the indole ring. | + | |
| − | AM-1710 — a CB2 selective cannabilactone with 54x selectivity over CB1. | + | *[[AM-855]] — an analgesic derivative of Δ8tetrahydrocannabinol, it is an agonist at both CB1 and CB2 with moderate selectivity for CB1, with a Ki of 22.3nM at CB1 and 58.6nM at CB2. |
| − | AM-1714 — a CB2 selective cannabilactone with 490x selectivity over CB1. | + | |
| − | AM-2201 — a potent agonist at both CB1 and CB2 with moderate selectivity for CB1, with a Ki of 1.0nM at CB1 and 2.6nM at CB2. | + | *AM-881 — a chlorine-substituted stereoisomer of anandamide whose Ki = 5.3nM at CB1 and 95nM at CB2. |
| − | AM-2212 — a potent agonist at both CB1 and CB2 with dodecal selectivity for CB1, with a Ki of 1.4nM at CB1 and 18.9nM at CB2. | + | |
| − | AM-2213 — a potent agonist at both CB1 and CB2 with 10x selectivity for CB1, with a Ki of 3.0M at CB1 and 30nM at CB2. | + | *AM-883 — an allyl-substituted stereoisomer of anandamide whose Ki = 9.9nM at CB1 and 226nM at CB2. |
| − | AM-2232 — a potent agonist at both CB1 and CB2, with a Ki of 0.28nM at CB1 and 1.48nM at CB2. | + | |
| − | AM-2233 — (R) enantiomer is potent and selective CB1 agonist used in 131I radiolabelled form to map distribution of CB1 receptors in brain. | + | *[[AM-905 ]]— a potent and reasonably selective agonist for the CB1 cannabinoid receptor, with a Ki of 1.2nM at CB1 and 5.3nM at CB2. |
| − | AM-2389 — classical cannabinoid derivative with 26x selectivity for CB1. | + | |
| − | AM-3102 — an analog of oleoylethanolamide, the endogenous agonist for proliferator-activated receptor α (PPARα). It also acts as a weak cannabinoid agonist with Ki values of 33µM at CB1 and 26µM at CB2. | + | *[[AM-906 ]]— a potent and dodecally selective agonist for the CB1 cannabinoid receptor, with a Ki of 0.8nM at CB1 and 9.5nM at CB2. |
| − | AM-4030 — a potent agonist at both CB1 and CB2, it is dodecally selective for CB1, with a Ki of 0.7nM at CB1 and 8.6nM at CB2. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families. | + | |
| − | AM-4054 — a potent but slow-onset agonist with CB1 affinity of 2.2nM and a 40x selectivity for CB1 over CB2. | + | *[[AM-919]] — a potent agonist at both CB1 and CB2 with moderate selectivity for CB1, with a Ki of 2.2nM at CB1 and 3.4nM at CB2. It is a derivative of [[HU-210]] and represents a hybrid structure between the classical and nonclassical cannabinoid families. |
| − | AM-4113 — a CB1 selective neutral antagonist. | + | |
| − | AM-6545 — a peripherally selective silent antagonist of CB1 receptors. | + | *AM-926 — a potent agonist at both CB1 and CB2 with moderate selectivity for CB1, with a Ki of 2.2nM at CB1 and 4.3nM at CB2. It is a derivative of [[HU-210]] and represents a hybrid structure between the classical and nonclassical cannabinoid families. |
| + | |||
| + | *[[AM-938]] — a potent agonist at both CB1 and CB2 with quadruple selectivity for CB2, with a Ki of 1.2nM at CB1 and 0.3nM at CB2. It is a derivative of [[HU-210]] and represents a hybrid structure between the classical and nonclassical cannabinoid families. | ||
| + | |||
| + | *AM-1116 — a dimethylated stereoisomer of anandamide whose Ki = 7.4nM at CB1. | ||
| + | |||
| + | *AM-1172 — an endocannabinoid analog specifically designed to be a potent and selective inhibitor of AEA uptake that is resistant to FAAH hydrolysis. | ||
| + | |||
| + | *[[AM-1220 ]]— a potent and selective analgesic CB1 agonist (as racemate) with a Ki of 3.88nM at CB1 and 73.4nM at CB2, giving it 19x selectivity for CB1. (R) enantiomer has around 1000x higher affinity for CB1 than (S) enantiomer. | ||
| + | |||
| + | *[[AM-1221 ]]— a potent and selective CB2 agonist with a Ki of 0.28nM at CB2 and 52.3nM at CB1, giving it a selectivity of almost 187x. | ||
| + | |||
| + | *[[AM-1235]] — a moderately CB1 selective agonist, with a Ki of 1.5nM at CB1 and 20.4nM at CB2, giving it a selectivity of around 13x. | ||
| + | |||
| + | *[[AM-1241 ]]— a potent and selective analgesic CB2 agonist with a Ki of 3.4nM at CB2 and 80x selectivity over CB1. | ||
| + | |||
| + | *[[AM-1248]] — a moderately potent agonist with some selectivity for CB1, containing an unusual 3-(adamant-1-oyl) substitution on the indole ring. | ||
| + | |||
| + | *AM-1710 — a CB2 selective cannabilactone with 54x selectivity over CB1. | ||
| + | |||
| + | *[[AM-1714 ]]— a CB2 selective cannabilactone with 490x selectivity over CB1. | ||
| + | |||
| + | *[[AM-2201 ]]— a potent agonist at both CB1 and CB2 with moderate selectivity for CB1, with a Ki of 1.0nM at CB1 and 2.6nM at CB2. | ||
| + | |||
| + | *AM-2212 — a potent agonist at both CB1 and CB2 with dodecal selectivity for CB1, with a Ki of 1.4nM at CB1 and 18.9nM at CB2. | ||
| + | |||
| + | *AM-2213 — a potent agonist at both CB1 and CB2 with 10x selectivity for CB1, with a Ki of 3.0M at CB1 and 30nM at CB2. | ||
| + | |||
| + | *[[AM-2232 ]]— a potent agonist at both CB1 and CB2, with a Ki of 0.28nM at CB1 and 1.48nM at CB2. | ||
| + | |||
| + | *[[AM-2233 ]]— (R) enantiomer is potent and selective CB1 agonist used in 131I radiolabelled form to map distribution of CB1 receptors in brain. | ||
| + | |||
| + | *[[AM-2389 ]]— classical cannabinoid derivative with 26x selectivity for CB1. | ||
| + | |||
| + | *AM-3102 — an analog of oleoylethanolamide, the endogenous agonist for proliferator-activated receptor α (PPARα). It also acts as a weak cannabinoid agonist with Ki values of 33µM at CB1 and 26µM at CB2. | ||
| + | |||
| + | *[[AM-4030 ]]— a potent agonist at both CB1 and CB2, it is dodecally selective for CB1, with a Ki of 0.7nM at CB1 and 8.6nM at CB2. It is a derivative of [[HU-210]] and represents a hybrid structure between the classical and nonclassical cannabinoid families. | ||
| + | |||
| + | *AM-4054 — a potent but slow-onset agonist with CB1 affinity of 2.2nM and a 40x selectivity for CB1 over CB2. | ||
| + | |||
| + | *AM-4113 — a CB1 selective neutral antagonist. | ||
| + | |||
| + | *[[AM-6545]] — a peripherally selective silent antagonist of CB1 receptors. | ||
| + | |||
| + | |||
| + | == See also == | ||
| + | |||
| + | [[List of JWH cannabinoids]] | ||
Latest revision as of 21:02, 16 February 2015
Alexandros Makriyannis is a professor in the Department of Medicinal Chemistry at Northeastern University, where his research group has synthesized many new compounds with cannabinoid activity. Some of those are:
- AM-087 — an analgesic CB1 agonist derived from Δ8THC substituted with a side chain on the 3-position, it has a Ki of 0.43nM making it roughly 100x as potent as THC.
- AM-251 — an inverse agonist at the CB1 cannabinoid receptor that is structurally related to SR141716A (rimonabant), but has a higher binding affinity with a Ki value of 7.5nM.
- AM-281 — N-(morpholin-4-yl)-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide
- AM-356 — a synthetically created stable chiral analog of anandamide, it acts on the cannabinoid receptors with a Ki of 17.9nM at CB1 and 868nM at CB2.
- AM-374 — palmitylsulfonyl fluoride
- AM-381 — stearylsulfonyl fluoride
- AM-404 — an active metabolite of paracetamol (acetaminophen) and a likely inhibitor of fatty acid amide hydrolase (FAAH)
- AM-411 — an adamantyl-substituted derivative of Δ8THC, it is a potent and fairly selective CB1 full agonist with a Ki of 6.80nM. It is also a moderately potent CB2 agonist with a Ki of 52.0nM.
- AM-630 — a potent and selective inverse agonist for the cannabinoid receptor CB2, with a Ki of 32.1nM at CB2 and 165x selectivity over CB1, at which it acts as a weak partial agonist.
- AM-661 — 1-(N-methyl-2-piperidine)methyl-2-methyl-3-(2-iodo)benzoylindole
- AM-678 — another name for JWH-018, it is a full agonist at both cannabinoid receptors with some selectivity for CB2.
- AM-679 (cannabinoid) — an iodobenzoylindole which acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5nM at CB1 and 49.5nM at CB2.
- AM-694 — an iodobenzoylindole which acts as a potent and selective agonist for the CB1 cannabinoid receptor, with a Ki of 0.08nM at CB1 and 18x selectivity over the related CB2 receptor (1.44nM).
- AM-735 — 3-bornyl-Δ8-THC, a mixed CB1 / CB2 agonist with Ki of 8.9nM at CB1 and 7.4nM at CB2.
- AM-855 — an analgesic derivative of Δ8tetrahydrocannabinol, it is an agonist at both CB1 and CB2 with moderate selectivity for CB1, with a Ki of 22.3nM at CB1 and 58.6nM at CB2.
- AM-881 — a chlorine-substituted stereoisomer of anandamide whose Ki = 5.3nM at CB1 and 95nM at CB2.
- AM-883 — an allyl-substituted stereoisomer of anandamide whose Ki = 9.9nM at CB1 and 226nM at CB2.
- AM-905 — a potent and reasonably selective agonist for the CB1 cannabinoid receptor, with a Ki of 1.2nM at CB1 and 5.3nM at CB2.
- AM-906 — a potent and dodecally selective agonist for the CB1 cannabinoid receptor, with a Ki of 0.8nM at CB1 and 9.5nM at CB2.
- AM-919 — a potent agonist at both CB1 and CB2 with moderate selectivity for CB1, with a Ki of 2.2nM at CB1 and 3.4nM at CB2. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families.
- AM-926 — a potent agonist at both CB1 and CB2 with moderate selectivity for CB1, with a Ki of 2.2nM at CB1 and 4.3nM at CB2. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families.
- AM-938 — a potent agonist at both CB1 and CB2 with quadruple selectivity for CB2, with a Ki of 1.2nM at CB1 and 0.3nM at CB2. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families.
- AM-1116 — a dimethylated stereoisomer of anandamide whose Ki = 7.4nM at CB1.
- AM-1172 — an endocannabinoid analog specifically designed to be a potent and selective inhibitor of AEA uptake that is resistant to FAAH hydrolysis.
- AM-1220 — a potent and selective analgesic CB1 agonist (as racemate) with a Ki of 3.88nM at CB1 and 73.4nM at CB2, giving it 19x selectivity for CB1. (R) enantiomer has around 1000x higher affinity for CB1 than (S) enantiomer.
- AM-1221 — a potent and selective CB2 agonist with a Ki of 0.28nM at CB2 and 52.3nM at CB1, giving it a selectivity of almost 187x.
- AM-1235 — a moderately CB1 selective agonist, with a Ki of 1.5nM at CB1 and 20.4nM at CB2, giving it a selectivity of around 13x.
- AM-1241 — a potent and selective analgesic CB2 agonist with a Ki of 3.4nM at CB2 and 80x selectivity over CB1.
- AM-1248 — a moderately potent agonist with some selectivity for CB1, containing an unusual 3-(adamant-1-oyl) substitution on the indole ring.
- AM-1710 — a CB2 selective cannabilactone with 54x selectivity over CB1.
- AM-1714 — a CB2 selective cannabilactone with 490x selectivity over CB1.
- AM-2201 — a potent agonist at both CB1 and CB2 with moderate selectivity for CB1, with a Ki of 1.0nM at CB1 and 2.6nM at CB2.
- AM-2212 — a potent agonist at both CB1 and CB2 with dodecal selectivity for CB1, with a Ki of 1.4nM at CB1 and 18.9nM at CB2.
- AM-2213 — a potent agonist at both CB1 and CB2 with 10x selectivity for CB1, with a Ki of 3.0M at CB1 and 30nM at CB2.
- AM-2232 — a potent agonist at both CB1 and CB2, with a Ki of 0.28nM at CB1 and 1.48nM at CB2.
- AM-2233 — (R) enantiomer is potent and selective CB1 agonist used in 131I radiolabelled form to map distribution of CB1 receptors in brain.
- AM-2389 — classical cannabinoid derivative with 26x selectivity for CB1.
- AM-3102 — an analog of oleoylethanolamide, the endogenous agonist for proliferator-activated receptor α (PPARα). It also acts as a weak cannabinoid agonist with Ki values of 33µM at CB1 and 26µM at CB2.
- AM-4030 — a potent agonist at both CB1 and CB2, it is dodecally selective for CB1, with a Ki of 0.7nM at CB1 and 8.6nM at CB2. It is a derivative of HU-210 and represents a hybrid structure between the classical and nonclassical cannabinoid families.
- AM-4054 — a potent but slow-onset agonist with CB1 affinity of 2.2nM and a 40x selectivity for CB1 over CB2.
- AM-4113 — a CB1 selective neutral antagonist.
- AM-6545 — a peripherally selective silent antagonist of CB1 receptors.
